2. Protein Tyrosine Kinase/RTK Neuronal Signaling
  3. c-Met/HGFR Trk Receptor
  4. Zurletrectinib

Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma.

For research use only. We do not sell to patients.

Zurletrectinib

Zurletrectinib Chemical Structure

CAS No. : 2403703-30-8

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Zurletrectinib Related Antibodies

Top Publications Citing Use of Products

View All Trk Receptor Isoform Specific Products:

View All Isoforms
TrkA TrkB TrkC Trk

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Zurletrectinib is a brain-penetrant, orally active TRK inhibitor (TRKA IC50 = 0.81 nM; TRKB IC50 = 0.145 nM; TRKC IC50 = 0.184 nM). Zurletrectinib exhibits stronger activity as a consequence of its augmented binding affinity for TRK kinases. Zurletrectinib exhibits higher activity against most TRK inhibitor resistance mutations (13 out of 18 mutations). Zurletrectinib can be used for the study of glioma[1].

IC50 & Target[1]

TrkA

0.81 nM (IC50)

TrkB

0.145 nM (IC50)

TrkC

0.184 nM (IC50)

In Vitro

Zurletrectinib (72 h) shows IC50 values of 0.47 nM and 7.2 nM against IRC (LMNA-NTRK1) and Kor1 (TPM3-NTRK1) cell lines, respectively[1].
Zurletrectinib remains active against resistance mutations to first-generation TRK inhibitors (such as G595R), but is less effective against certain xDFG mutations (such as G667C)[1].
Zurletrectinib (72 h) can inhibit the growth of IRC (LMNA-NTRK1) single mutant G595R cell lines and TRK phosphorylation, but its effect on double mutants (G595R/G667C) is limited[1].
Zurletrectinib has inhibitory activity against NLS (Bcan-Ntrk1) single mutations (such as G598R) and double mutations (such as G598R/G670A)[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Zurletrectinib Related Antibodies
In Vivo

Zurletrectinib (0.1-3 mg/kg, p.o., bid, for 10-23 days) exhibits potent antitumor activity against NTRK fusion-positive xenograft tumors (KM12; Ba/F3 LMNA-NTRK1 TRKA G595R) in mice with a high safety profile[1].
Zurletrectinib (15 mg/kg, bid) demonstrates potent antitumor activity against tumors, particularly TRK double-mutant tumors, in a mouse intracranial Bcan–Ntrk1 orthotopic transplantation model[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: KM12 and Ba/F3 LMNA-NTRK1, TRKA G595R xenografts were generated by subcutaneous injection of five and six million cells into the right flank of 6–8 weeks old BALB/c nude female mice, respectively[1].
Dosage: KM12: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg
Ba/F3 LMNA-NTRK1, TRKA G595R: 0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration: p.o., BID, 10-23 days
Result: 1 mg/kg significantly inhibited KM12 tumor growth.
No significant weight loss or toxicity was observed.
Low-dose administration significantly inhibited Ba/F3 LMNA-NTRK1, TRKA G595R tumor growth.
Remained potent against TRKA G595R-resistant models.
Clinical Trial
Molecular Weight

415.40

Formula

C19H19F2N7O2
CAS No.
Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C1NC2=C3N=C(N4[C@@](C[C@@](F)([H])C4)([H])C5=CC(F)=CN=C5O[C@](C)([H])CN1)C=CN3N=C2
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
Solvent & Solubility
In Vitro: 

DMSO : 10 mg/mL (24.07 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.4073 mL 12.0366 mL 24.0732 mL
5 mM 0.4815 mL 2.4073 mL 4.8146 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 1 mg/mL (2.41 mM); Clear solution

    This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.4073 mL 12.0366 mL 24.0732 mL 60.1830 mL
5 mM 0.4815 mL 2.4073 mL 4.8146 mL 12.0366 mL
10 mM 0.2407 mL 1.2037 mL 2.4073 mL 6.0183 mL
15 mM 0.1605 mL 0.8024 mL 1.6049 mL 4.0122 mL
20 mM 0.1204 mL 0.6018 mL 1.2037 mL 3.0091 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Zurletrectinib Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Zurletrectinib2403703-30-8ICP-723ICP723ICP 723c-Met/HGFRTrk ReceptorTropomyosin related kinase receptorTRK inhibitorsTRK resistance mutationsGliomaBrain penetrationInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Zurletrectinib
Cat. No.:
HY-148811
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (252 KB) Français - FR (252 KB) Deutsch - DE (252 KB) Norwegian - NO (252 KB) Español - ES (252 KB) Swedish - SV (252 KB) Italian - IT (252 KB) Korean - KR (252 KB) Portuguese - PT (252 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.